The effect of Atenolol on the blood pressure were studied in 31 cases of essential hypertension and on the effect of plasma renin activity in 8 cases. There were 8 cases of male with age 49.5(42-70) and 23 cases of female with age 49(35-71) years. 27 cases of 31 cases were untreated hypertensive patients and 4 cases were refractory to hypotensive drugs of diuretics and vasodilators. The Atenolol 50mg once-daily was given to all patients orally for 3 weeks. The blood pressure, heart rate, ECG and symptoms were checked in one week interval. In 8 cases, the plasma renin activity was measured by Dainabot Kit before and after one week medication. The results were as follows: 1. In 27 cases of untreated hypertension, the control blood pressure was 182.9/11.4mmHg in average. The blood pressure decreased in average by 18.3/11mmHg in one week, 23.7/15.9mmHg in two week and 21.5/10.5mmHg in three week. The heart rate also decreased by 7.4/min. in one week, 14.9/min. in two week and 7.8/min. in three week. These data showed considerable reduction of blood pressure and heart rate with 50mg Atenolol once-daily. 2. The basal plasma renin activity after one week medication was reduced by 46% in 8 cases and this data showed considerable reduction regardless control level of basal plasma renin activity. 3. There were considerable blood pressure reduction by adding Atenolol 50mg once-daily to diuretics and vasodilator to which patient's blood pressures were refractory. 4. There was no orthostatic hypotension or serious side effect by Atenolol medication.
Atenolol ; Blood Pressure* ; Diuretics ; Electrocardiography ; Female ; Heart Rate ; Humans ; Hypertension* ; Hypotension, Orthostatic ; Male ; Plasma* ; Renin* ; Vasodilator Agents

Small cell carcinoma in the ampulla of Vater is rare, and the concurrent occurrence of adenocarcinoma and small cell carcinoma is extremely rare. We report the case of a double primary tumor, adenocarcinoma and small cell carcinoma, in the ampulla of Vater.
Adenocarcinoma ; Ampulla of Vater ; Carcinoma, Small Cell

No abstract available.
Animals ; Dogs* ; Heart* ; Heart-Lung Transplantation*

OBJECTIVE: The goal of this study was to clarify the value of the programmable valve shunt system to readjust the pressure noninvasively for the adequate cerebrospinal fluid(CSF) drainage. METHODS: The authors analyzed a single-center retrospective study of 54 patients suffering from hydrocephalus of various causes, as aneurysm(21 patients), trauma(13 patients), normal-pressure hydrocephalus(NPH, 7 patients) and so on. In 51 cases a programmable valve was implanted at the first shunt implantation. In three cases the shunt was replaced to a programmable valve system. RESULTS: In 33 patients(61%) of cases valve pressure adjustment was required at least once(total number of readjustment 54, mean 1.7, maximum 5) for the reason of underdrainage(36) or overdrainge(18). The range of reprogrammed valve pressure was 10 to 90mmH2O(mean 11.1+/-15.9mmH2O), the radiological finding improved 48.6% of frontal horn index at the beginning of reprogramming to 41.3%, and the clinical symptom related with hydrocephalus improved in 29 patients(87.8%) of pressure adjustment. Shunt reprogramming was necessary in patients with congenital hydrocephalus(100%), aneurysm(55%), NPH(71%), trauma(50%); the programmable valve proved particularly beneficial for overdrainge as subdural hygroma. CONCLUSION: The programmable valve was useful for the correction of overdrainge or underdrainage by the easy control of valve pressure without any invasive procedure.
Animals ; Drainage ; Horns ; Humans ; Hydrocephalus* ; Retrospective Studies ; Subdural Effusion